Literature DB >> 17332976

Antiphospholipid antibodies in HIV-positive patients.

Liliana Galrão1, Carlos Brites, Maria Luíza Atta, Ajax Atta, Isabella Lima, Fernanda Gonzalez, Fernanda Magalhães, Mittermayer Santiago.   

Abstract

Antiphospholipid (aPL) antibodies classically have been associated with thrombotic phenomena and abortion in patients with autoimmune diseases. The objective of the present work was to evaluate the frequency of such antibodies in patients infected with HIV and study its association with the presence of clinical manifestations of antiphospholipid syndrome (APS). Using a transversal study, a population of patients diagnosed with HIV, identified through an enzyme-linked immunosorbent assay (ELISA) test and confirmed by Western blotting, aged above 17 years old, was investigated. Through a standard questionnaire, the presence of APS manifestations was investigated, as well as the frequency of rheumatic manifestations. Antibodies against beta2 glycoprotein I (anti-beta2 GPI) and anticardiolipin (aCL) IgA, IgG, and IgM were investigated by the ELISA method using commercial kits (QUANTA Lite, INOVA Diagnostics). Ninety patients were studied, 47 (52.2%) male and 43 (47.8%) female. Clinical manifestations of APS were detected in 12 patients (13.3%) of the studied population, whereas arthralgia was the most common rheumatic manifestation (38.9%). Of the 90 patients, 40 (44.4%) were reactive for at least one type of aPL antibody (aCL and/or anti-beta2 GPI). The frequency of aCL was 17.8%, from which 15 (16.7%) had aCL IgG, 3 (3.3%) IgM, and 1 (1.1%) IgA. The frequency of the anti-beta2 GPI antibody was 33.3%, from which 29 (32.2%) were positive for isotype IgA, 4 (4.4%) isotype IgM, and 1 (1.1%) isotype IgG. No association was observed between immunoreactivity for aPL antibodies in general or each isotype in particular and the presence of APS manifestation. In the present study, it was possible to observe a relatively high frequency of aPL antibodies, particularly for isotype IgA anti-beta2 GPI in HIV. However, there was no association to APS manifestations, suggesting that such antibodies had no etiopathogenic role in these complications in patients with such retroviral infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332976     DOI: 10.1007/s10067-007-0581-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  41 in total

1.  Antibodies to cardiolipin and beta2-glycoprotein-1 in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Z Faghiri; W A Wilson; F Taheri; E N Barton; O S Morgan; A E Gharavi
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications.

Authors:  M Harada; Y Fujisawa; S Sakisaka; T Kawaguchi; E Taniguchi; M Sakamoto; S Sumie; K Sasatomi; H Koga; T Torimura; T Ueno; K Gondo; H Yoshida; K Tanikawa; M Sata
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

3.  Antiphospholipid syndrome induced by HIV.

Authors:  A N Leder; B Flansbaum; G Zandman-Goddard; R Asherson; Y Shoenfeld
Journal:  Lupus       Date:  2001       Impact factor: 2.911

4.  Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

Authors:  C Petrovas; P G Vlachoyiannopoulos; T Kordossis; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

5.  Recurrent cerebral infarcts as the first manifestation of infection with the HIV virus.

Authors:  Izabela Gorczyca; Mirosława Stanek; Beata Podlasin; Mariusz Furmanek; Jarosław Pniewski
Journal:  Folia Neuropathol       Date:  2005       Impact factor: 2.038

6.  Autoantibodies directed against phospholipids or human beta 2-glycoprotein I in HIV-seropositive patients: relationship with endothelial activation and antimalonic dialdehyde antibodies.

Authors:  J Constans; V Guérin; A Couchouron; M Seigneur; A Ryman; A D Blann; J Amiral; A Amara; E Peuchant; J F Moreau; I Pellegrin; J L Pellegrin; H Fleury; B Leng; C Conri
Journal:  Eur J Clin Invest       Date:  1998-02       Impact factor: 4.686

7.  Psoriatic arthritis and human immunodeficiency virus infection in Zambia.

Authors:  P Njobvu; P McGill
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

8.  Prevalence of antiphospholipid antibodies in patients with chronic liver disease related to alcohol or hepatitis C virus: correlation with liver injury.

Authors:  C Biron; H Andréani; P Blanc; J Ramos; J Ducos; N Guigue; H Michel; D Larrey; J F Schved
Journal:  J Lab Clin Med       Date:  1998-03

9.  Anticardiolipin antibodies in chronic viral hepatitis. Do they have clinical consequences?

Authors:  José R Yuste; Jesús Prieto
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-07       Impact factor: 2.566

10.  IgA antiphospholipid antibodies in HTLV-1-associated tropical spastic paraparesis.

Authors:  W A Wilson; C Morgan Ost; E N Barton; M Smikle; B Hanchard; W A Blattner; S Doggett; A E Gharavi
Journal:  Lupus       Date:  1995-04       Impact factor: 2.911

View more
  14 in total

Review 1.  Infections and the antiphospholipid syndrome.

Authors:  Mario García-Carrasco; Claudio Galarza-Maldonado; Claudia Mendoza-Pinto; Ricardo O Escarcega; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

2.  Hyperhomocysteinemia in HIV-Infected Individuals: Correlation of a Frequent Prothrombotic Factor with CD4+ Cell Count.

Authors:  Alireza Abdollahi; Tahereh Sanaei Shoar
Journal:  Oman Med J       Date:  2012-05

3.  Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.

Authors:  Albert M Anderson; Tanea Chane; Manish Patel; Shuo Chen; Wenqiong Xue; Kirk A Easley
Journal:  AIDS Patient Care STDS       Date:  2012-06-28       Impact factor: 5.078

4.  Serum concentrations of antiphospholipid and anticardiolipin antibodies are higher in HIV-infected women.

Authors:  Alireza Abdollahi; Afsaneh Morteza
Journal:  Rheumatol Int       Date:  2011-03-30       Impact factor: 2.631

5.  Analysis of the Coagulation Profile in Children with HIV Infection-Effect of Disease and Anti Retroviral Therapy.

Authors:  Priya Thomas; Sunita Sharma; Jagdish Chandra; Anita Nangia; Shivali Sehgal
Journal:  Indian J Hematol Blood Transfus       Date:  2021-05-05       Impact factor: 0.900

6.  Antiphospholipid syndrome and acute HIV infection.

Authors:  Jaime Solis Diaz; Juan Gomez Octavio; Manuel L Fernandez-Guerrero
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

7.  HIV stroke risk: evidence and implications.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah L Commins; William Yong; Margrit Carlson
Journal:  Ther Adv Chronic Dis       Date:  2013-03       Impact factor: 5.091

Review 8.  Evolving spectrum of HIV-associated rheumatic syndromes.

Authors:  Christine Fox; Karen Walker-Bone
Journal:  Best Pract Res Clin Rheumatol       Date:  2015-05-23       Impact factor: 4.098

Review 9.  Kaleidoscope of autoimmune diseases in HIV infection.

Authors:  Justyna Roszkiewicz; Elzbieta Smolewska
Journal:  Rheumatol Int       Date:  2016-08-20       Impact factor: 3.580

10.  Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.

Authors:  Kathryn A K Finton; Kevin Larimore; H Benjamin Larman; Della Friend; Colin Correnti; Peter B Rupert; Stephen J Elledge; Philip D Greenberg; Roland K Strong
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.